ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
The FDA will reconsider Atara Biotherapeutics’ rare cancer drug Ebvallo after initially rejecting it due to manufacturing concerns.
The FDA will reconsider Atara Biotherapeutics’ rare cancer drug Ebvallo after initially rejecting it due to manufacturing concerns.
The FDA will reconsider Atara Biotherapeutics’ rare cancer drug Ebvallo after initially rejecting it due to manufacturing concerns.
The FDA will reconsider Atara Biotherapeutics’ rare cancer drug Ebvallo after initially rejecting it due to manufacturing concerns.
The FDA will reconsider Atara Biotherapeutics’ rare cancer drug Ebvallo after initially rejecting it due to manufacturing concerns.
Tom Kertscher, PolitiFact Covid-19 vaccines have killed 676,000 Americans. Steve Kirsch in an Aug. 6, 2023, blog post A blog
Read More
An important email appeared in the inboxes of a small group of health care workers north of Boston as this
Read More
Senate Minority Leader Mitch McConnell is “medically clear” to continue working, the attending physician for the U.S. Congress said one
Read More
August 31, 2023 3 min read Source/Disclosures Disclosures: Korczak reports receiving grants from the Canada Institutes of Health Research and
Read More
August 31, 2023 3 min read Source/Disclosures Disclosures: Mehta reports receiving a training grant from the Consortium of Eosinophilic Gastrointestinal
Read More
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk,
Read More
Were the flaxseed studies showing 20 pounds of weight loss just flukes? Canada now allows a health claim on the
Read More
August 31, 2023 2 min read Source/Disclosures Published by: Disclosures: Tesch reports receiving funding support from the German Federal Ministry
Read More
Montana’s legislature designated $3.7 million this spring to remove lead from school drinking-water supplies, then the state received $565,000 more
Read More
August 30, 2023 2 min read Source/Disclosures Disclosures: Obara reports no relevant financial disclosures. Please see the study for all
Read More
